Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

NCT01636102 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Influenza

Interventions

BIOLOGICAL: Trivalent influenza virus vaccine (TIV)

Sponsor

Novartis Vaccines